Author

Anyway Brenda Kapingidza

Duke UniversityORCID 0000-0001-8517-6299Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

Brianna RhodesiD· 3 shared Barton F. HaynesiD· 2 shared Caitlin HarrisiD· 2 shared Daniel J. MarstoniD· 2 shared Daniel WrappiD· 2 shared Kevin J. WieheiD· 2 shared McKenzie Frazier· 2 shared Mihai L. AzoiteiiD· 2 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Brianna RhodesORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintNov 4, 2025

Iterative immunogen optimization to focus elicited responses on a conserved, subdominant influenza hemagglutinin epitope

Daniel J. Marston, Akiko Watanabe, Anyway Brenda Kapingidza…·Mihai L. Azoitei

The paper designs immunogens that redirect immune responses to a conserved influenza epitope using iterative machine learning and in vivo testing.

2 citations

proteomicsdeep learning

𝕏 PostBluesky

ImmunologyJournal of VirologyPeer-reviewedJun 13, 2025

Design of SARS-CoV-2 RBD Immunogens to Focus Immune Responses Towards Conserved Coronavirus Epitopes

Caitlin Harris, Anyway Brenda Kapingidza, James Emmanuel San…·Mihai L. Azoitei

This paper designs SARS-CoV-2 RBD immunogens that shift immune responses towards conserved epitopes, improving cross-reactivity against variants.

8 citationstop 3%

protein structureexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintJul 8, 2024

HLA-E-VL9 antibodies enhance NK cell and CD8+ T cell cytotoxicity against HIV-infected CD4+ T cells

Joyce K Hwang, Daniel J. Marston, Marina Tuyishime…·Mihai L. Azoitei

This study develops anti-HLA-E-VL9 antibodies that enhance NK and CD8+ T cell cytotoxicity against HIV-infected cells by blocking NKG2A/CD94 interactions and promoting ADCC.

2 citations

humanproteomics

𝕏 PostBluesky